Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Devore Best

Psychiatry Deerfield, IL Medical Doctor

NPI 1730201567 CMS profile 953435

440 Lake Cook Rd, Suite 2, Deerfield, IL 60015

Open in the dashboard

General payments

$14,194

766 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Devore Best of Deerfield, IL is reported in the CMS Open Payments database as having received $14,194 across 766 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,559 124
2024 General $1,966 101
2023 General $2,148 108
2022 General $2,075 120
2021 General $2,622 157
2020 General $1,514 109
2019 General $1,311 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Devore Best
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Steven Devore Best were reported at $2,559. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Steven Devore Best Psychiatry median Middle half National median
2019 $1,311 $184 $59–$605 $163
2020 $1,514 $119 $36–$372 $114
2021 $2,622 $143 $43–$576 $132
2022 $2,075 $153 $50–$590 $149
2023 $2,148 $170 $56–$651 $160
2024 $1,966 $179 $57–$673 $164
2025 $2,559 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,770 112 payments
  2. Harmony Biosciences LLC $1,432 83 payments
  3. Alkermes, Inc. $1,143 51 payments
  4. Lundbeck LLC $1,066 67 payments
  5. ITI, Inc. $976 44 payments
  6. Otsuka America Pharmaceutical, Inc. $913 49 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $719 33 payments
  8. Jazz Pharmaceuticals Inc. $678 22 payments
  9. Teva Pharmaceuticals USA, Inc. $556 30 payments
  10. Allergan Inc. $512 44 payments
  11. Other $4,429 231 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,573 747 payments
  2. Education $621 19 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $1,134 68 payments
  2. ARISTADA Cns $1,075 48 payments
  3. ARISTADA Cns $1,075 48 payments
  4. ARISTADA Cns $911 39 payments
  5. ARISTADA Cns $911 39 payments
  6. REXULTI Psychiatry $777 42 payments
  7. LYBALVI $696 35 payments
  8. ARISTADA INITIO $611 25 payments
  9. CAPLYTA $606 26 payments
  10. REXULTI Psychiatry $598 35 payments
  11. Other $11,044 600 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

517

Median for Psychiatry: 574

Drug cost

$36,318

Median for Psychiatry: $27,624

Branded share of claims

12.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 19 $21,575
Clozapine Generic 40 $3,023
Depakote Er Divalproex Sodium Brand 12 $2,729
Armodafinil Generic 26 $1,169
Methylphenidate Hcl Generic 26 $995
Buprenorphine Hcl Generic 24 $987
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $953
Clonazepam Generic 72 $678
Trazodone Hcl Generic 14 $460
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 17 $443

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$319 — —
CAPLYTA
$250 19 —
VRAYLAR
$215 — —
ARISTADA
$129 — —
Auvelity
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

766 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record